Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > catecholamines market
Get a free sample of Catecholamines Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Catecholamines Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The growing geriatric population represents a significant growth driver for the catecholamines market. As the global population ages, the incidence of age-related health conditions and chronic diseases increases. For instance, according to the Public Library of Science (PLOS) report, about 21% of the elderly in India reportedly have at least one chronic disease. The report also stated that, 17% elderly in rural areas and 29% in urban areas suffer from a chronic disease. Hypertension and diabetes account for about 68% of all chronic diseases. Therefore, catecholamines, with their ability to rapidly improve hemodynamic parameters, are poised to be a foundation in the management of acute exacerbations and complications arising from chronic conditions. Such aforementioned factor is anticipated to boost the market growth.
North America held 40.8% share of the catecholamines industry in 2022 and is anticipated to witness considerable growth rate through 2032 owing to presence of advanced healthcare infrastructure and higher emphasis on emergency medical care.
The epinephrine type segment held 49.4% of the catecholamines industry share in 2022 and is projected to witness significant growth through 2032 driven by the rising prevalence of allergies and increased awareness of anaphylactic reactions worldwide.
Catecholamines industry size crossed USD 3.9 billion in 2022 and is estimated to reach USD 7.6 billion by end of 2032 due to the surge in technological advancements in drug delivery systems.
The hospital pharmacy distribution channel segment recorded 49.8% of the catecholamines industry share in 2022 due to the surging need for ensuring the timely availability, accurate preparation, and proper administration of critical medications.